Urogen Pharma Ltd (URGN) returns
Urogen Pharma returns over 5 years
$1,000 invested in Urogen Pharma five years ago was worth $1,902 at the close on October 30, 2026, with dividends reinvested: an average return of 13.7% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -19.5% | — | $805.32 | -0.9% |
| 3 months | -20.4% | — | $796.30 | +2.1% |
| Year to date | +39.7% | — | $1,397 | +11.7% |
| 1 year | +64.8% | — | $1,648 | +12.4% |
| 3 years | +201.0% | +44.4% | $3,010 | +88.5% |
| 5 years | +90.2% | +13.7% | $1,902 | +76.0% |
Urogen Pharma return by calendar year
| Year | URGN | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +39.7% | +11.7% | +28.0% |
| 2025 | +119.9% | +17.7% | +102.2% |
| 2024 | -29.0% | +24.9% | -53.9% |
| 2023 | +69.1% | +26.2% | +42.9% |
| 2022 | -6.7% | -18.2% | +11.4% |
| 2021 | -47.2% | +28.7% | -76.0% |
| 2020 | -46.0% | +18.4% | -64.4% |
| 2019 | -22.5% | +31.2% | -53.7% |
| 2018 | +15.7% | -4.6% | +20.3% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: URGN financials
No forecast, no recommendation. This page describes Urogen Pharma Ltd from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.